Ikena Oncology completes merger with Inmagene, becomes ImageneBio, raises $75M private placement

ImageneBio, Inc.

Merger closed July 25, 2025; combined company renamed ImageneBio, Inc., trading on Nasdaq under IMA starting July 28.
Concurrent $75.0M private placement from investors including Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors.
Legacy Inmagene holders own ~55% (pre-financing) or ~43.1% (post-financing); Ikena holders own ~45% (pre) or ~35.3% (post); new investors own ~21.6%.
ImageneBio to advance IMG-007 Phase 2b trial in moderate-to-severe atopic dermatitis; topline readout expected Q4 2026.
Kristin Yarema, Ph.D. appointed CEO; Ikena implemented a 1-for-12 reverse stock split prior to closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.